Our Pipeline
Our vision is to harness our Pointillist Platform to develop a pipeline of high therapeutic index precision oncology medicines.
By targeting tumor-specific cell surface epitopes, we are unlocking an approach to precision oncology drug discovery that is modality-agnostic, enabling the development of next generation high therapeutic index oncology therapeutics. We believe that our epitope-focused strategy can be applied broadly—selecting the optimal modality and product concept to match the unmet needs of tumor targets and target biology.
Stipple Bio’s lead candidate, STP-100, is a novel Antibody Drug Conjugate (ADC) with a clinically validated linker payload incorporating tumor-specific binders designed to avoid on-target/off-tumor toxicity.